Albert David enters into co-marketing agreement for Placenta Products; Stock gains 1.5%

Co-Marketing is a well-established strategic process used by “parent companies” to help expand the product reach.

Oct 05, 2021 12:10 IST India Infoline News Service

Men shaking hands
Albert David Ltd has informed that Placentrex, the human placental extract product, is an old and well-established product of the company. It is used by the Gynecologists for PID (Pelvic Inflammatory Disease) and by Surgeons, Physicians and other doctors for difficult to heal wounds.

Co-Marketing is a well-established strategic process used by “parent companies” to help expand the product reach/market, thus offering the product benefits to a larger number of end users. Further, Albert David has decided to partner with Corona Remedies Private Limited to help take the ‘Placenta Products, with another brand name, to a larger and wider group of end beneficiaries, the company said.

With the above objective, Albert David and Corona Remedies Limited have entered into a strategic Co-Marketing Agreement on October 4, 2021.

On Tuesday, at around 12:17 PM, Albert David was trading at Rs612.35 apiece up by Rs9.2 or 1.53% on the BSE.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity